Analyzing R&D Budgets: Perrigo Company plc vs Iovance Biotherapeutics, Inc.

A Decade of R&D: Perrigo vs. Iovance

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Iovance Biotherapeutics, Inc. and Perrigo Company plc have taken distinct paths in their R&D investments.

Iovance's Meteoric Rise

From 2014 to 2023, Iovance's R&D expenses skyrocketed by over 12,000%, starting from a modest $2.7 million to a staggering $344 million. This reflects Iovance's aggressive push towards pioneering cancer immunotherapies, underscoring its commitment to cutting-edge research.

Perrigo's Steady Course

Conversely, Perrigo's R&D spending has seen a more conservative trajectory, peaking in 2018 at $218 million before stabilizing around $122 million in recent years. This trend highlights Perrigo's strategic focus on maintaining its position in the consumer healthcare market.

As these two companies chart their courses, their R&D strategies offer a fascinating glimpse into the diverse approaches within the pharmaceutical industry.